Ocular Delivery (OcD)

Ocular Delivery (OcD)

The use of drug delivery systems to offer increased safety and utility of ocular therapeutics is a rapidly evolving and ever growing field. Controlled release systems have been employed to both reformulate existing drugs and design new drugs to meet the high potential for commercial interest and patient benefit. The Ocular Delivery Focus Group will support the mission of CRS by engaging researchers, industry representatives, and regulatory experts in the advancement of technologies designed to protect or restore vision. The members of the Focus Group are expected to be paid members of the Controlled Release Society, independent of their membership category. We will also reach out to former or inactive members of CRS and other non-members in the vision research community whose work may benefit from the Focus Group to encourage their participation. This may include notable professional societies in ophthalmology like the Association for Research in Vision and Ophthalmology (ARVO) and the International Society for Eye Research (ISER).

The members of the Focus Group are expected to be paid members of the Controlled Release Society, independent of their membership category.

Access the member-only community



Therapeutic Delivery via the Suprachoroidal Space - A New Era in the Treatment of Retinal Diseases

Development of Ophthalmic Emulsions from Bench to Bedside: a Scientific and Human story




Qingguo Xu
Virginia Commonwealth University
Vice Chair
Crystal Shin
Baylor College of Medicine
Industry Representative
Bindhu Rayaprolu
Associate Director, Regeneron
Communications Chair
Katelyn E. Swindle-Reilly
Assistant Professor, Ohio State University
Ravi Sheshala
Senior Lecturer, Universiti Teknologi MARA (UiTM), Malaysia)
Academic Representative
Rocio Herrero Vanrell
Professor, Complutense University, Madrid, Spain
Postdoc Trainee
Karim Soliman
McMaster University
Graduate Trainee Representative
Mishra Deepkkumar
Queen’s University Belfast